Share on StockTwits

Zafgen (NASDAQ:ZFGN) released its earnings data on Wednesday. The company reported ($2.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $2.68, Analyst Ratings Network.com reports.

A number of research firms have recently commented on ZFGN. Analysts at Canaccord Genuity initiated coverage on shares of Zafgen in a research note on Wednesday. They set a “buy” rating and a $36.00 price target on the stock. On the ratings front, analysts at JMP Securities initiated coverage on shares of Zafgen in a research note on Tuesday, July 29th. They set an “outperform” rating and a $31.00 price target on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of Zafgen in a research note on Wednesday, July 23rd. They set an “outperform” rating and a $35.00 price target on the stock.

Zafgen (NASDAQ:ZFGN) traded up 0.51% during mid-day trading on Wednesday, hitting $17.83. 19,997 shares of the company’s stock traded hands. Zafgen has a 52 week low of $17.06 and a 52 week high of $21.01. The stock has a 50-day moving average of $18.55 and a 200-day moving average of $18.65. The company’s market cap is $388.8 million.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.